Innoskel
Gene therapies for patients with rare skeletal diseases, including SEDc
Highlights
- New on EvolcAdded 2026-11-11
About Innoskel
InnoSkel is a biotechnology company developing therapies for rare skeletal diseases. Its lead asset is a gene therapy for SEDc, a severe form of type 2 collagenopathy.
The company aims to improve skeletal growth and reduce complications for people with skeletal dysplasia. It announced a Series A financing round co-led by Jeito Capital and Vida Ventures.
Founded in 2020, InnoSkel is headquartered in Biot, France.
Product: Gene therapy candidates for rare skeletal diseases, including SEDc.
Jobs at Innoskel
More biotech & pharma companies
Innovative Diagnostics
PCR and ELISA test kits for diagnosing zoonotic and veterinary infectious diseases, sold to laboratories worldwideInnovhem
Biomarker assays and clinical research services for pharma, biotech and clinicians working on sickle cell diseaseNew on EvolcInnovi
Research and development laboratory for organizations developing food, nutrition, cosmetics, crop protection and bio-based materialsInorevia
Benchtop walk-away automation for NGS library prep, sold to genomics core labs, clinical labs and biotech R&D teamsNew on EvolcInovarion
Contract biomedical research services for pharma and biotech teams, from discovery and preclinical work to regulatory affairsInovotion
In vivo oncology efficacy and toxicity assays for drug developers and cancer researchersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.